Zealand Pharma: trial met primary endpoint

Zealand Pharma: trial met primary endpoint

Zealand Pharma A/S (ZEAL) reported positive topline results from its Phase 2 ZUPREME-1 trial of petrelintide, an amylin analog for weight management, meeting its primary endpoint of statistically significant body weight reduction in participants with overweight or obesity. The trial demonstrated a mean weight reduction of up to 10.7% at week 42 compared to 1.7% with placebo (p-value <0.001), with no treatment discontinuations due to gastrointestinal adverse events at the maximally effective dose according to trial results. The study, which enrolled 493 participants across 33 sites in the U.S., Poland, and Romania, also showed sustained efficacy through week 42 and high adherence to dose escalation as reported.

The results support further development of petrelintide as a monotherapy and combination therapy, with Phase 3 trials planned for 2026 according to company announcements. Zealand Pharma highlighted the drug's potential to address unmet needs in obesity treatment, citing its tolerability profile and mechanism of action targeting leptin sensitivity as detailed in press releases.

The company's pipeline includes multiple late-stage programs, including Phase 3 trials for survodutide (a glucagon/GLP-1 dual agonist) and glepaglutide (for short bowel syndrome), as well as a collaboration with Roche for petrelintide's commercialization according to market analysis. Zealand Pharma will host a conference call today to discuss the findings as scheduled.

ZEAL's stock, which has traded between DKK 306.10 and DKK 788.00 over the past year, closed at DKK 390.40 on March 5, 2026, up 0.62% according to market data. The company is positioned to deliver key data across its portfolio in 2026, with potential regulatory milestones and trial readouts expected to drive investor interest.